make semaglutide Novo asks FDA to bar compounders from making copies Semaglutide Tablets

Factores econmicos y acceso: El costo elevado de estos medicamentos y las limitaciones de cobertura de seguros pueden afectar la viabilidad del tratamiento a largo plazo

doi:10.1016/j.cct.2024.107516 14 Loomba R et al.: Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis

Oct 9: In a relatively rare move, the FDA went against the recommendation of one of its advisory committees, rejecting a bid by Alnylam to expand Onpattro (patisiran)s label to cardiomyopathy of transthyretin-mediated amyloidosis

Rapid systemic signaling during abiotic and biotic stresses: is the ROS wave master of all trades

It expands access to GLP-1s beyond those with clinical obesity recognizing their potential benefits beyond weight alone

Methanethiol and dimethylsulfide formation from 3-methylthiopropionate in human and rat hepatocytes